Mepolizumab, an anti-interleukin (IL)-5 monoclonal antibody, is approved for use in hypereosinophilic syndrome (HES), a group of disorders characterized by peripheral eosinophilia and eosinophil-induced organ dysfunction. The gene discussed is IL5; the disease is hypereosinophilic syndrome.